Atenolol as a comparator in outcome trials in hypertension: A correct choice in the past, but not for the future? Review uri icon

Overview

MeSH Major

  • Adrenergic beta-Antagonists
  • Angiotensin II Type 1 Receptor Blockers
  • Blood Pressure
  • Calcium Channel Blockers
  • Cardiovascular Diseases
  • Hypertension

abstract

  • Beta-blocker-based antihypertensive therapy significantly reduces cardiovascular risk in hypertension compared with placebo or no treatment. Atenolol was an appropriate comparator in the LIFE study. As the results of the LIFE study and other recent trials demonstrate superiority of newer agents over atenolol, this agent is not an appropriate reference drug for future trials of cardiovascular risk in hypertension.

publication date

  • May 7, 2007

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1080/08037050701246386

PubMed ID

  • 17453746

Additional Document Info

start page

  • 6

end page

  • 12

volume

  • 16

number

  • 1